Literature DB >> 3947531

Dose-response relationship for phenobarbitone promotion of liver tumours initiated by single dose dimethylnitrosamine.

H E Driver, A E McLean.   

Abstract

A single dose of 15 mg/kg dimethylnitrosamine is an initiator of hepatic tumour formation in rats but does not produce tumours without further treatment. Subsequent promotion by Na phenobarbitone (1000 micrograms/ml drinking water) leads to 40% or more of the rats developing hepatocellular carcinoma. Four days of dietary treatment designed to produce a wave of DNA synthesis at the time of initiation leads to an even greater yield of tumours and nodules after promotion. This effect of phenobarbitone does not appear to be directly related to its ability to induce enzyme activity in the liver because lower doses of phenobarbitone (100 micrograms/ml or less) did not promote tumour development in spite of being adequate for the induction of cytochrome P-450 and associated enzyme activity. A similar incidence of hepatocellular carcinoma was found in both the groups given DMN and the top dose of Na phenobarbitone (1000 micrograms/ml) whether or not they had been given the dietary pretreatment. However, hyperplastic nodules were seen only in the diet pre-treated group. This is discussed in relation to the hypothesis that hyperplastic nodules are precursors of hepatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3947531      PMCID: PMC2013072     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN: 0007-1021


  13 in total

1.  The effect of diet on the toxicity of paracetamol and the safety of paracetamol-methionine mixtures.

Authors:  A E McLean; P A Day
Journal:  Biochem Pharmacol       Date:  1975-01-01       Impact factor: 5.858

2.  Enhancing effect of phenobarbital on the development of enzyme-altered islands and hepatocellular carcinomas initiated by 3'-methyl-4-(dimethylamino) azobenzene or diethylnitrosamine.

Authors:  T Kitagawa; H Sugano
Journal:  Gan       Date:  1978-10

3.  Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene.

Authors:  C Peraino; R J Fry; E Staffeldt
Journal:  Cancer Res       Date:  1971-10       Impact factor: 12.701

4.  The effect of oral phenobarbitone on hepatic microsomal cytochrome P-450 and demethylation activity in rats fed normal and low protein diets.

Authors:  W J Marshall; A E McLean
Journal:  Biochem Pharmacol       Date:  1969-01       Impact factor: 5.858

5.  Effects of varying the dietary concentration of phenobarbital on its enhancement of 2-acetylaminofluorene-induced hepatic tumorigenesis.

Authors:  C Peraino; E F Staffeldt; D A Haugen; L S Lombard; F J Stevens; R J Fry
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

6.  Rapid emergence of carcinogen-induced hyperplastic lesions in a new model for the sequential analysis of liver carcinogenesis.

Authors:  D B Solt; A Medline; E Farber
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

7.  Histochemical studies on the early proliferative lesion induced in the rat liver by aflatoxin.

Authors:  W H Butler; V Hempsall; M G Stewart
Journal:  J Pathol       Date:  1981-04       Impact factor: 7.996

8.  Differences between small and large intestine and liver in the inducibility of microsomal enzymes in response to stimulation by phenobarbitone and betanaphthoflavone in the diet.

Authors:  R E McDanell; A E McLean
Journal:  Biochem Pharmacol       Date:  1984-06-15       Impact factor: 5.858

9.  Long-term administration of DDT or phenobarbital-Na in Wistar rats.

Authors:  L Rossi; M Ravera; G Repetti; L Santi
Journal:  Int J Cancer       Date:  1977-02-15       Impact factor: 7.396

10.  Long-term effects of phenobarbitone-Na on male Fischer rats.

Authors:  W H Butler
Journal:  Br J Cancer       Date:  1978-03       Impact factor: 7.640

View more
  1 in total

Review 1.  Dose-response relationship in multistage carcinogenesis: promoters.

Authors:  K T Kitchin; J L Brown; R W Setzer
Journal:  Environ Health Perspect       Date:  1994-01       Impact factor: 9.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.